AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00619476
Drug: GEn 2400mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gabapentin enacarbil 2400mg/day
Trial: NCT00619476
Drug: GEn 3600mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gabapentin enacarbil 3600mg/day
Trial: NCT00619476
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT01560468
Drug: ITX 5061
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg given orally beginning at the time of liver transplantation and for 1 week post-transplant followed by 150 mg orally for an additional 21 days.
Trial: NCT03806049
Drug: TSR042
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given as IV infusion every three weeks
Trial: NCT02462083
Drug: IDP-118 Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDP-118 lotion will be applied as per the instructions provided by the investigational center staff.
Trial: NCT03244592
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg/day
Trial: NCT00640081
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00640081
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00640081
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03131583
Drug: SHR4640
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day3\~Day8 qd
Trial: NCT04298021
Drug: AZD6738
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * In AZD6738+Durvalumab cohort~  - AZD6738 240 mg bid on D15-D28 Every 4 weeks~* In AZD6738+ Olaparib cohort - AZD6738 160 mg qd on D1-7 Every 4 weeks
Trial: NCT00495586
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One pill to be taken every eight hours for 8 days
Trial: NCT02429050
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in the control group will receive placebo, consisting of microcrystalline cellulose (FMC BioPolymer). Hard gelatin capsules of size AA in Swedish orange containing microcrystalline cellulose will be produced.
Trial: NCT00171249
Drug: STI571 400 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STI571 capsules and tablets
Trial: NCT00171249
Drug: STI571 600 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STI571 capsules and tablets
Trial: NCT03821038
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV twice a week at the same volume for 3 weeks
Trial: NCT02174757
Drug: Inersan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic
Trial: NCT02174757
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antibiotic
Trial: NCT02527343
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volanesorsen-matching placebo administered SC injection.
Trial: NCT00211185
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide will be administered IV at a dosage of 750 milligrams/meter squared (mg/m\^2) on Day 3 of each 21-day cycle for 6 cycles, with a maximum of 8 cycles.
Trial: NCT00211185
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin will be administered IV at a dosage of 50 mg/m\^2 on Day 3 of each 21-day cycle for 6 cycles, with a maximum of 8 cycles.
Trial: NCT02873091
Drug: sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00712673
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self administered by subcutaneous injections once daily within the hour preceding meal (either breakfast or dinner).
Trial: NCT01852162
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets
Trial: NCT04062695
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablets containing placebo
Trial: NCT03936569
Drug: Marketed Toothpaste
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marketed stannous fluoride (0.454%) toothpaste
Trial: NCT03936569
Drug: Marketed Cavity Protection Toothpaste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marketed sodium monofluorophosphate (0.76 %) toothpaste
Trial: NCT01268059
Drug: MEDI-575
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI-575 at a dose of 25 milligram per kilogram (mg/kg) administered as an IV infusion once every 21 days on Day 1 for a total of 6 cycles until unacceptable toxicity, disease progression, initiation of alternative anticancer therapy, or other reasons for participant withdrawal. MEDI-575 alone continued in those participants who achieved stable disease or better at the completion of carboplatin/paclitaxel therapy and did not demonstrate toxicity to MEDI-575.
Trial: NCT01474512
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT02749708
Drug: IRX5183
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IRX5183 will be administered orally daily on days 1-28 of each cycle for 2 cycles of induction. In the phase I part of the study, there will be 3 dose levels (dose level 1 \[DL1\] with 50 mg, DL2 with 75 mg, and DL3 with 100 mg), with 1 additional dose level to be only used if excessive toxicity noted at the DL1. There will be no intra-patient dose escalation. A phase II portion of the study was originally planned, but the study was terminated prior to phase II enrollment.
Trial: NCT01142999
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This group will be asked NOT to use any skin moisturizers and use only soap substitutes on their infants.
Trial: NCT01468831
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg of minocycline in a pink opaque capsule
Trial: NCT00083564
Drug: STR(TM) (Skeletal Targeted Radiotherapy, Holmium-166-DOTMP)
RxNorm normalized name: holmium
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01232283
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identically matching placebo by mouth BID for first 16 weeks. Placebo participants will be switched to receive apremilast 30 mg BID at Week 16-32.
Trial: NCT00986414
Drug: AFQ056
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00986414
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03826563
Drug: oral melatonin tablets (NatureMade brand)
RxNorm normalized name: melatonin Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: melatonin tablets
Trial: NCT03232177
Drug: Anagre Cap.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: from 0.5mg twice a day to maximally increase total10mg in 8 weeks and maintain maximal tolerable dose to 104 weeks
Trial: NCT00465530
Drug: Gentamycin
RxNorm normalized name: Gentamicin Sulfate 3 MG/1 ML Ophthalmic Solution [GENTAMYCIN]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal irrigation
Trial: NCT01338324
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin 20 mg single dose on day 1
Trial: NCT01742611
Drug: ASP1585
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT02022514
Drug: Conventional medical treatment
RxNorm normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00975936
Drug: [14C]-GSK706769
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50µg \[14C\]-GSK706769 containing 250 nCi
Trial: NCT01198912
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: during 56 days
Trial: NCT01198912
Drug: doxycycline 100 mg
RxNorm normalized name: doxycycline 100 MG
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: during 56 days
Trial: NCT04346316
Drug: SHR0302
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets taken once daily (QD)
Trial: NCT00794664
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mL weekly subcutaneous injections for 26 weeks
Trial: NCT03080831
Drug: Glucion 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study fluid used at maintenance rate of 27 mmol per kg of body weight per day from beginning of surgery until end of study.
Trial: NCT03219437
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: capsule
Trial: NCT04872283
Drug: IV Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive 30mg of intravenous (IV) ketorolac will be given during surgery
Trial: NCT04872283
Drug: Ketorolac Pill
RxNorm normalized name: ketorolac Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 20 tablets of 10mg ketorolac, with instructions to take 1 tablet orally every 6 hours for pain
Trial: NCT04872283
Drug: 5/325mg Oxycodone-Acetaminophen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 30 tablets of 5/325mg oxycodone-acetaminophen with instructions to take 1 or 2 tablets by mouth every 4 to 6 hours as needed for pain
Trial: NCT04872283
Drug: Aspirin 81Mg Ec Tab
RxNorm normalized name: ASPIRIN 81MG EC TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 81 mg aspirin twice daily as a preventive measure against deep venous thrombosis (DVT)
Trial: NCT02344823
Drug: Placebo intake once daily
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02937844
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 250 mg/m\^2, d1-3
Trial: NCT00175227
Drug: intravenous saline hydration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mls half-normal saline
Trial: NCT01994668
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single intravenous administration of 0.9% saline over 1 minute
Trial: NCT03567681
Drug: Extended release oxcarbazepine vs Immediate release oxcarbazepine
RxNorm normalized name: oxcarbazepine Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended release oxcarbazepine vs Immediate release oxcarbazepine
Trial: NCT03383185
Drug: Progestin-only pills
RxNorm normalized name: Prostin E2 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of progestin-only pills during the follow-up period
Trial: NCT01798251
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: capecitabine 850mg/m2 bid, d1-14, every 3 weeks
Trial: NCT00124332
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04509115
Drug: Short-acting opioid prescription for acute pain
RxNorm normalized name: Short-acting sulfonamides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients not currently using opioids who receive a new short-acting opioid prescription as part of routine care for acute pain will be recruited and followed prospectively for 180 days.
Trial: NCT02534038
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo
Trial: NCT00264927
Drug: SR121463B
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00402597
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 placebo tablet twice daily for 6 months.
Trial: NCT01831856
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration, one capsule each evening with dinner.
Trial: NCT02886728
Drug: Placebo to match MTX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule(s) administered orally once weekly
Trial: NCT01602562
Drug: VACV tablets (Adults or pediatrics) or granules (pediatrics)
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A white to slightly yellowish white film coated tablet contains 556 mg of valaciclovir hydrochloride (500 mg of valaciclovir)). VACV granules have no or slightly specific odor.
Trial: NCT03933488
Drug: TAK-994 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-994 placebo-matching tablets.
Trial: NCT03071601
Drug: Lidocaine 1% Epinephrine 0.005mg/mL solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anesthesia by subcutaneous injection of a solution containing 1% Lidocaine and 0.005mg/mL Epinephrine in and around the wound in the minutes preceding the suture of the wound
Trial: NCT04494373
Drug: Xgeva®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A human IgG2 monoclonal antibody with affinity and specificity for human RANKL
Trial: NCT00865475
Drug: Switching to LPV/r monotherapy (Kaletra)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients on AZT+3TC+ABV with viral suppression will be randomized to keep on vs switching to LPV/r
Trial: NCT02481947
Drug: BLI400 Laxative
RxNorm normalized name: LAXATIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 21 gm BLI400 powder
Trial: NCT00757341
Drug: SKI-606
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02949310
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01468415
Drug: phenol
RxNorm normalized name: Phenol
DrugBank: Phenol (DB03255)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 cc of 8% phenol dissolved in water or 20cc of 8o mg Methylprednisolone diluted in 0.25% marcaine.
Trial: NCT02171416
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03836664
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is normal saline solution that will be supplied in container matched to Timolol container.
Trial: NCT02357459
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 5 mL IA injection
Trial: NCT02357459
Drug: TCA IR 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 1 mL IA injection
Trial: NCT04025216
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive cyclophosphamide and fludarabine lymphodepletion chemotherapy followed by the investigational product, CART-TnMUC1
Trial: NCT03052205
Drug: IMO-2125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMO-2125 will be administered by intratumoral injection on Days 1, 8, and 15 of Cycle 1 and on Day 1 of each subsequent cycle.
Trial: NCT02873689
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexlansoprazole placebo-matching capsules
Trial: NCT00238862
Drug: Autologous serum/BSS 20%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00907257
Drug: Tretinoin gel
RxNorm normalized name: Tretinoin Gel
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.04% tretinoin gel
Trial: NCT01152671
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral dose
Trial: NCT01152671
Drug: RO5024048
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral dose
Trial: NCT04361656
Drug: PEG-ELS current standard of care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care for inpatient colonoscopy
Trial: NCT04016974
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets once daily throughout the treatment period (day 1 to 84)
Trial: NCT03531281
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01762891
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: celecoxib 200mg/day by oral rout during 15 days followed by the administration of rofecoxib 25mg/day, acetaminophen 3g/day and placebo during 15 days each drug.
Trial: NCT01762891
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 3g/ was given during 15 days by oral rout following one of the other interventions or as the final intervention.
Trial: NCT01762891
Drug: Rofecoxib
RxNorm normalized name: Rofecoxib
DrugBank: Rofecoxib (DB00533)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rofecoxib 25mg/day was given by oral rout during 15 days following one or more interventions or as the final intervention.
Trial: NCT01762891
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pills were given during 15 days by oral rout as one of the four interventions.
Trial: NCT00679627
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT00641563
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infusion of remifentanil
Trial: NCT04059003
Drug: Taxanes or/and anthracycline-based therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taxanes or/and anthracycline-based therapy will be used in this group. That is, intravenous injection of 90 mg/m2 epirubicin (trade name: Pharmorubicin, Pfizer, Shanghai, China; drug approval number: H20100155) + 135 mg/m2 paclitaxel liposome (trade name: Taxotere, Sanofi (Hangzhou) Pharmaceutical Co., Ltd., Hangzhou, China; drug approval number: J20090104), every 3 weeks as a course of treatment. The efficacy will be evaluated every 2 courses. After the 6th course, mastectomy will be performed according to the patient's conditions.
Trial: NCT03300115
Drug: AC0010
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After subjects prove eligible after screening and are enrolled, they are given AC0010 300 mg Bid (the two doses are advised to be administered at an interval of 12 hours), receive evaluation of safety indicators every 3 weeks, efficacy evaluation every 6 weeks until disease progression or intolerable toxicities or withdrawal from the trial. (If the investigator suspects disease progression, CT or MRI may be performed in advance; if the patient does not have disease progression, subsequent efficacy evaluation will proceed still according to the protocol).
Trial: NCT01886378
Drug: UX007
RxNorm normalized name: UX007
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02039453
Drug: fentanyl doses
RxNorm normalized name: fentanyl Metered Dose Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fentanyl doses 50μg (37.5kg to 62.5kg), 75μg (62.5kg to 87.5kg), 100μg (\>87.5kg), single use Propofol doses 1.0mg/kg IV bolus loading, 20mg, IV bolus, titration (up to MOAAS 5)
Trial: NCT03255941
Drug: Sayana Press
RxNorm normalized name: garden cress sprout extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The safety and effectiveness of provision of injectable contraception will be compared between providers' screening and counseling for eligibility to use Sayana Press
Trial: NCT00372060
Drug: Comparator: placebo (unspecified)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily for 12 weeks
Trial: NCT01285609
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01271647
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: granules,18g per time,two times per day,six months
Trial: NCT02053103
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, 0 mg, twice daily, 6 weeks
Trial: NCT03994380
Drug: RhDNAse Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhDNAse 2.5 mg nebulizer daily for 4 weeks
Trial: NCT03056989
Drug: SPX-101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation solution twice daily for 7 days.
Trial: NCT04694092
Drug: Standard approach to heart rate control
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard heart rate control with intravenous or oral beta-blockers and/or antiarrhythmic in combination with digoxin
Trial: NCT00657111
Drug: CS-8958 formulated as dry powder
RxNorm normalized name: MyoGesic-CS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CS-8958, formulated as a dry-powder and will be administered from capsules containing 5 mg CS-8958 and lactose to 25 mg (placebo) inserted into a FlowCaps inhaler device.
Trial: NCT00386594
Drug: 852A
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02726178
Drug: Advil® Pediatric drops for infants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study the effect of inhibition of prostaglandins with ibuprofen vs placebo administration on cardio respiratory events in preterms infants
Trial: NCT02726178
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study the effect of inhibition of prostaglandins with ibuprofen vs placebo administration on cardio respiratory events in preterms infants
Trial: NCT02821390
Drug: Nepafenac Eye Drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One drop instilled to the eye's cul de sac prior to the intravitreal injection.
Trial: NCT02821390
Drug: Placebo (Artificial Tears)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One drop instilled to the eye's cul de sac prior to the intravitreal injection